Project Details
Description
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
Status | Active |
---|---|
Effective start/end date | 9/28/23 → 5/31/33 |
Funding
- TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.